I perform video–assisted thoracic surgery (VATS) procedures for the removal of lung tumors and tumors in the mediastinum. VATS provides a significant advantage over traditional thoracotomy incisions as it’s minimally invasive and promotes rapid healing with fewer infections. VATS lobectomy is becoming the operation of choice for early stage lung cancer.
My research interest involves tumor immunology. I have investigated the role of Ciplatin mediated upregulation of CD40 ligand in lung cancer cell lines. CD8 T cells contain the CD40 ligand receptor that promotes cancer cell apoptosis, or programmed death, after binding CD40 ligand. I also perform outcomes research to improve the results of surgical procedures for thoracic malignancies.
In 2015, I was rated in the top 10 percent of physicians in the nation for patient satisfaction. I’ve published many studies in Nature Medicine, The Annals of Thoracic Surgery, Thoracic Surgery Clinics, The Journal of Thoracic and Cardiovascular Surgery, Journal for Immunotherapy of Cancer and Rapid Communications in Mass Spectrometry.
Here at OSUCCC – James, we work together as a multidisciplinary team to improve patient care and outcomes while striving to find the cure for cancer. It’s challenging and rewarding work, and we never stop trying.
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2016
Cornell University Medical College
New York Presbyterian Hospital
7/1/1999 - 6/18/2004
Specialties and conditions I treat
- Thoracic Surgery
- Thoracic Diseases
- Minimally Invasive Surgical Procedures
- Thoracic Surgery, Video-Assisted
- Esophageal Cancers
- Esophageal Diseases
- Mediastinal Diseases
- Pleural Effusion
- Lung Cancers
- Carcinoma, Non-Small-Cell Lung
- Tracheal Diseases
- Thoracic Surgery
Locations where I practice
More about my work
Cardio Thoracic Surgery
Massachusetts General Hospital
7/1/2005 - 12/31/2007
American Board of Surgery
American Board of Thoracic Surgery
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Merritt has reported no financial relationships with medical device, research and/or drug companies.